{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:27Z","timestamp":1787064627563,"version":"build-2736575974"},"reference-count":140,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Growing evidence suggests that neuroinflammation is not just a consequence of neurodegeneration in pathologies such as Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease or Amyotrophic lateral sclerosis, but it is rather a determinant factor, which plays a pivotal role in the onset and progression of these disorders. Neuroinflammation can affect cells and processes in the central nervous system (CNS) as well as immune cells, and might precede protein aggregation, which is a hallmark of the neurodegenerative process. Standard treatment methods are far from being able to counteract inflammation and delay neurodegeneration. Remarkably, phosphodiesterase 5 inhibitors (PDE5is), which represent potent vasoactive drugs used as a first-line treatment for erectile dysfunction (ED), display important anti-inflammatory effects through cyclic guanosine monophosphate (cGMP) level stabilization. Since PDE5 hydrolyzes cGMP, several studies positioned PDE5 as a therapeutic target, and more specifically, PDE5is as potential alternative strategies for the treatment of a variety of neurological disorders. Indeed, PDE5is can limit neuroinflammation and enhance synaptic plasticity, with beneficial effects on cognitive function and memory. The aim of this review is to provide an overview of some of the main processes underlying neuroinflammation and neurodegeneration which may be potential targets for PDE5is, focusing on sildenafil, the most extensively studied. Current strategies using PDEis for the treatment of neurodegenerative diseases will be summarized.<\/jats:p>","DOI":"10.3390\/cells13201720","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:19:18Z","timestamp":1729163958000},"page":"1720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Emerging Role of Phosphodiesterase 5 Inhibition in Neurological Disorders: The State of the Art"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-3114","authenticated-orcid":false,"given":"Clara","family":"Crescioli","sequence":"first","affiliation":[{"name":"Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Piazza Lauro de Bosis, 6, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5324-0903","authenticated-orcid":false,"given":"Maria Paola","family":"Paronetto","sequence":"additional","affiliation":[{"name":"Department of Movement, Human and Health Sciences, University of Rome Foro Italico, Piazza Lauro de Bosis, 6, 00135 Rome, Italy"},{"name":"Laboratory of Molecular and Cellular Neurobiology, Fondazione Santa Lucia IRCCS, Via del Fosso di Fiorano, 64, 00143 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.coph.2011.10.003","article-title":"Phosphodiesterase function and endocrine cells: Links to human disease and roles in tumor development and treatment","volume":"11","author":"Levy","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: Inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCRESAHA.116.306082","article-title":"Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of \u03b2-adrenoceptor-stimulated contractility in early cardiac hypertrophy","volume":"116","author":"Perera","year":"2015","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1091\/mbc.e09-08-0655","article-title":"Compartmentalized cyclic adenosine 3\u2032,5\u2032-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains","volume":"21","author":"Penmatsa","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BJ20090842","article-title":"Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: Effects of caveolin-1 knockdown on formation\/maintenance of macromolecular signalling complexes","volume":"424","author":"Ahmad","year":"2009","journal-title":"Biochem. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3940(95)11323-O","article-title":"Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer\u2019s disease","volume":"187","author":"Bonkale","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semcancer.2018.08.011","article-title":"Targeting the paracrine hormone-dependent guanylate cyclase\/cGMP\/phosphodiesterases signaling pathway for colorectal cancer prevention","volume":"56","author":"Yarla","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27403","DOI":"10.18632\/oncotarget.4741","article-title":"Suppression of \u03b2-catenin\/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature14332","article-title":"Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease","volume":"519","author":"Lee","year":"2015","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Schudt, C., Hatzelmann, A., Beume, R., and Tenor, H. (2011). Phosphodiesterase inhibitors: History of pharmacology. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-642-17969-3_1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0976500X221129008","article-title":"A Review on the Pharmacological Importance of PDE5 and Its Inhibition to Manage Biomedical Conditions","volume":"13","author":"Saikia","year":"2022","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/1062936X.2021.1989721","article-title":"First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis","volume":"32","author":"Nandi","year":"2021","journal-title":"SAR QSAR Environ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ahmed, W.S., Geethakumari, A.M., and Biswas, K.H. (2021). Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. Biomed. Pharmacother., 134.","DOI":"10.1016\/j.biopha.2020.111128"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cruz-Burgos, M., Losada-Garcia, A., Cruz-Hern\u00e1ndez, C.D., Cort\u00e9s-Ram\u00edrez, S.A., Camacho-Arroyo, I., Gonzalez-Covarrubias, V., Morales-Pacheco, M., Trujillo-Bornios, S.I., and Rodr\u00edguez-Dorantes, M. (2021). New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.627229"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2174\/138161206778343064","article-title":"Expression, distribution and regulation of phosphodiesterase 5","volume":"12","author":"Lin","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd2058","article-title":"Phosphodiesterases in the CNS: Targets for drug development","volume":"5","author":"Menniti","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/14779072.4.3.293","article-title":"Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension","volume":"4","author":"Hemnes","year":"2006","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12950-015-0099-7","article-title":"The role of phosphodiesterase-5 inhibitors in prostatic inflammation: A review","volume":"12","author":"Peixoto","year":"2015","journal-title":"J. Inflamm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11064-006-9187-7","article-title":"Cyclic GMP-dependent pathways protect differentiated oligodendrocytes from multiple types of injury","volume":"32","author":"Benjamins","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.intimp.2010.12.017","article-title":"Sildenafil attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK\/NF-\u03baB signaling pathways in N9 microglia","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/15376510601003769","article-title":"Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress","volume":"17","author":"Khoshakhlagh","year":"2007","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_26","unstructured":"Mizuno, T. (2024). Neuroinflammation\u2014PDE Family Inhibitors in the Regulation of Neuroinflammation. Encyclopedia of Neuroscience, Springer."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00210-012-0730-6","article-title":"cGMP becomes a drug target","volume":"385","author":"Schlossmann","year":"2012","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"940207","DOI":"10.1155\/2015\/940207","article-title":"Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition","volume":"2015","author":"Peixoto","year":"2015","journal-title":"Mediators Inflamm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00702-005-0409-y","article-title":"Molecular mechanisms involved in T cell migration across the blood-brain barrier","volume":"113","author":"Engelhardt","year":"2006","journal-title":"J. Neural. Transm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0165-5728(00)00298-8","article-title":"Molecular mechanisms and Th1\/Th2 pathways in corticosteroid regulation of cytokine production","volume":"109","author":"Kovalovsky","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106082","DOI":"10.1016\/j.intimp.2019.106082","article-title":"cGMP signaling pathway in hepatic encephalopathy neuroinflammation and cognition","volume":"79","author":"Peixoto","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.niox.2018.10.006","article-title":"Pharmacological manipulation of cGMP and NO\/cGMP in CNS drug discovery","volume":"82","author":"Hollas","year":"2019","journal-title":"Nitric Oxide"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.STR.0000158923.19956.73","article-title":"Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor","volume":"36","author":"Zhang","year":"2005","journal-title":"Stroke"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0306-4522(95)00349-N","article-title":"Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase","volume":"69","author":"Boulton","year":"1995","journal-title":"Neuroscience"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/mol.63.6.1322","article-title":"Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole","volume":"63","author":"Chien","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.neuint.2004.03.021","article-title":"Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation","volume":"45","author":"Contestabile","year":"2004","journal-title":"Neurochem. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.12.006","article-title":"A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons","volume":"21","author":"Riccio","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zinni, M., Pansiot, J., L\u00e9ger, P.L., El Kamouh, M., and Baud, O. (2021). Sildenafil-Mediated Neuroprotection from Adult to Neonatal Brain Injury: Evidence, Mechanisms, and Future Translation. Cells, 10.","DOI":"10.3390\/cells10102766"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.exer.2006.09.010","article-title":"cAMP-responsive element binding protein mediates a cGMP\/protein kinase G-dependent anti-apoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells","volume":"84","author":"Nakamura","year":"2007","journal-title":"Exp. Eye Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/cdd.2014.11","article-title":"The nitric oxide-cGKII system relays death and survival signals during embryonic retinal development via AKT-induced CREB1 activation","volume":"21","author":"Socodato","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainresrev.2008.03.002","article-title":"Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs","volume":"58","author":"Rego","year":"2008","journal-title":"Brain Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1007\/s11033-023-08650-8","article-title":"Modulating cyclic nucleotides pathways by bioactive compounds in combatting anxiety and depression disorders","volume":"50","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/JAD-151104","article-title":"PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease","volume":"52","author":"Teich","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Ricobaraza","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1523\/JNEUROSCI.5291-04.2005","article-title":"Amyloid-beta peptide inhibits activation of the nitric oxide\/cGMP\/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity","volume":"25","author":"Puzzo","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_47","first-page":"150","article-title":"Versatile effects of sildenafil: Recent pharmacological applications","volume":"59","author":"Uthayathas","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3233\/JAD-231391","article-title":"Sildenafil as a Candidate Drug for Alzheimer\u2019s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons","volume":"98","author":"Gohel","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1007\/s00415-022-11196-7","article-title":"Resurrection of sildenafil: Potential for Huntington\u2019s Disease, too?","volume":"269","author":"Achenbach","year":"2022","journal-title":"J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer\u2019s disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbapap.2003.11.019","article-title":"Cdk5, a therapeutic target for Alzheimer\u2019s disease?","volume":"1697","author":"Tsai","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","article-title":"Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"164","author":"Hervias","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.expneurol.2013.10.021","article-title":"Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions","volume":"251","author":"Prado","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2014.01.012","article-title":"Revised diagnostic criteria of multiple sclerosis","volume":"13","author":"Milo","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awp289","article-title":"Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis","volume":"132","author":"Stuerner","year":"2009","journal-title":"Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.21652","article-title":"T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta","volume":"65","author":"Durelli","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1471-4159.2010.07136.x","article-title":"Synergistic activity of interleukin-17 and tumor necrosis factor-\u03b1 enhances oxidative stress-mediated oligodendrocyte apoptosis","volume":"116","author":"Paintlia","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106581","DOI":"10.1016\/j.intimp.2020.106581","article-title":"Effect of sildenafil on neuroinflammation and synaptic plasticity pathways in experimental autoimmune encephalomyelitis","volume":"85","author":"Marinho","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Averaimo, S., and Nicol, X. (2014). Intermingled cAMP, cGMP and calcium spatiotemporal dynamics in developing neuronal circuits. Front. Cell. Neurosci., 8.","DOI":"10.3389\/fncel.2014.00376"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kleppisch, T. (2009). Phosphodiesterases in the central nervous system. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-68964-5_5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1523\/JNEUROSCI.4873-07.2008","article-title":"Embryonically expressed GABA and glutamate drive electrical activity regulating neurotransmitter specification","volume":"28","author":"Root","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrn2056","article-title":"Neuronal polarity: From extracellular signals to intracellular mechanisms","volume":"8","author":"Arimura","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zuccarello, E., Acquarone, E., Calcagno, E., Argyrousi, E.K., Deng, S.X., Landry, D.W., Arancio, O., and Fiorito, J. (2020). Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer\u2019s disease. Biochem. Pharmacol., 176.","DOI":"10.1016\/j.bcp.2020.113818"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sheng, J., Zhang, S., Wu, L., Kumar, G., Liao, Y., Gk, P., and Fan, H. (2022). Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer\u2019s disease. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.1019187"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.arcmed.2012.11.001","article-title":"Introductory remarks. Molecular, biological and clinical aspects of Alzheimer\u2019s disease","volume":"43","author":"Maccioni","year":"2012","journal-title":"Arch Med. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106970","DOI":"10.1016\/j.phrs.2023.106970","article-title":"Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?","volume":"197","author":"Nelissen","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neubiorev.2020.02.004","article-title":"Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot","volume":"113","author":"Argyrousi","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","article-title":"Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus","volume":"19","author":"Lu","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/MCB.23.16.5726-5737.2003","article-title":"Activation of the phosphatidylinositol 3-kinase\/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis","volume":"23","author":"Kawasaki","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/376074a0","article-title":"Activity-dependent long-term enhancement of transmitter release by presynaptic 3\u2032,5\u2032-cyclic GMP in cultured hippocampal neurons","volume":"376","author":"Arancio","year":"1995","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35055104","article-title":"Protein S-nitrosylation: A physiological signal for neuronal nitric oxide","volume":"3","author":"Jaffrey","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13024-019-0326-4","article-title":"Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade","volume":"14","author":"Acquarone","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(97)01301-0","article-title":"Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinast","volume":"337","author":"Prickaerts","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbr.2005.04.021","article-title":"The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices","volume":"164","author":"Rutten","year":"2005","journal-title":"Behav. Brain Res."},{"key":"ref_76","first-page":"318","article-title":"Sildenafil improves acquisition and retention of memory in mice","volume":"47","author":"Singh","year":"2003","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00008877-199912000-00004","article-title":"Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice","volume":"10","author":"Baratti","year":"1999","journal-title":"Behav. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","article-title":"Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques","volume":"196","author":"Rutten","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/NRE-131022","article-title":"Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline","volume":"34","author":"Devan","year":"2014","journal-title":"NeuroRehabilitation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/0269881119885262","article-title":"Pro-cognitive effect of upregulating cyclic guanosine monophosphate signalling during memory acquisition or early consolidation is mediated by increased AMPA receptor trafficking","volume":"34","author":"Argyrousi","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acschemneuro.7b00345","article-title":"Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer\u2019s Disease","volume":"9","author":"Mao","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1017\/S1461145713001533","article-title":"Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP\/PS1 transgenic mice by stimulation of NO\/cGMP signalling","volume":"17","author":"Jin","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mad.2015.07.002","article-title":"A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP\/PS1 transgenic mice model","volume":"150","author":"Zhu","year":"2015","journal-title":"Mech. Ageing Dev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2012.12.009","article-title":"Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Fiorito","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.7b00979","article-title":"Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer\u2019s Disease","volume":"60","author":"Fiorito","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","article-title":"Selective phosphodiesterase inhibitors: A promising target for cognition enhancement","volume":"202","author":"Reneerkens","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neuropharm.2015.04.019","article-title":"PDE5 inhibition improves acquisition processes after learning via a central mechanism","volume":"97","author":"Akkerman","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.brainresbull.2019.09.001","article-title":"Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer\u2019s disease","volume":"153","author":"Liu","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1023\/A:1017573722074","article-title":"Sildenafil (Viagra): Is there an influence on psychological performance?","volume":"32","author":"Grass","year":"2001","journal-title":"Int. Urol. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/PL00007092","article-title":"Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: A study with event-related brain potentials","volume":"19","author":"Schultheiss","year":"2001","journal-title":"World J. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s Disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2227738","DOI":"10.1001\/jamanetworkopen.2022.27738","article-title":"Association of Diet and Physical Activity with All-Cause Mortality Among Adults with Parkinson Disease","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ggi.12123","article-title":"Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson\u2019s disease","volume":"14","author":"Qi","year":"2014","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10048-016-0497-x","article-title":"Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinson\u2019s disease revealed different epigenetic patterns in peripheral blood mononuclear cells","volume":"18","author":"Kaut","year":"2017","journal-title":"Neurogenetics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/mds.26345","article-title":"A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration","volume":"30","author":"Azuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/brain\/awv219","article-title":"Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson\u2019s disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/j.1460-9568.2006.04816.x","article-title":"Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson\u2019s disease","volume":"23","author":"Galati","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref_98","first-page":"401","article-title":"Deep brain stimulation in Parkinson\u2019s disease patients: Biochemical evidence","volume":"70","author":"Stefani","year":"2006","journal-title":"J. Neural. Transm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02260966","article-title":"NADPH-diaphorase\/nitric oxide synthase containing neurons in normal and Parkinson\u2019s disease putamen","volume":"7","author":"Wolf","year":"1994","journal-title":"J. Neural Transm. Park. Dis. Dement. Sect."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.parkreldis.2011.07.003","article-title":"cGMP level in idiopathic Parkinson\u2019s disease patients with and without cardiovascular disease\u2014A pilot study","volume":"17","author":"Brodacki","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0022-510X(97)00267-0","article-title":"Cerebrospinal fluid cyclic guanosine 3\u20325\u2032 monophosphate levels in Parkinson\u2019s disease","volume":"155","author":"Navarro","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","article-title":"Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: New aspects in the pathogenetic mechanisms","volume":"28","author":"Giorgi","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neuint.2014.10.004","article-title":"Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?","volume":"79","author":"Sancesario","year":"2014","journal-title":"Neurochem. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1179\/135100001101536436","article-title":"Role of nitric oxide in a progressive neurodegeneration model of Parkinson\u2019s disease in the rat","volume":"6","author":"Barthwal","year":"2001","journal-title":"Redox Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.neuint.2007.02.002","article-title":"The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice","volume":"50","author":"Chalimoniuk","year":"2007","journal-title":"Neurochem. Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbrc.2004.09.028","article-title":"Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice","volume":"324","author":"Chalimoniuk","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuroscience.2014.12.008","article-title":"Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats","volume":"286","author":"Sharma","year":"2015","journal-title":"Neuroscience"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.expneurol.2007.02.010","article-title":"Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV","volume":"211","author":"Yang","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","article-title":"The pharmacology of selegiline","volume":"100","author":"Magyar","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/JHD-120023","article-title":"Cognitive Dysfunction in Huntington\u2019s Disease: Humans, Mouse Models and Molecular Mechanisms","volume":"1","author":"Giralt","year":"2012","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1172\/JCI85594","article-title":"Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington\u2019s disease","volume":"127","author":"Tanaka","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Saavedra, A., Giralt, A., Arum\u00ed, H., Alberch, J., and P\u00e9rez-Navarro, E. (2013). Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073664"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington\u2019s Disease Models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jns.2016.07.033","article-title":"Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington\u2019s disease gene carriers","volume":"368","author":"Wilson","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nbd.2012.11.016","article-title":"Phosphodiesterase 10A (PDE10A) localization in the R6\/2 mouse model of Huntington\u2019s disease","volume":"52","author":"Leuti","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/jpet.116.237388","article-title":"TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6\/2 Mouse Model of Huntington\u2019s Disease","volume":"360","author":"Harada","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/hmg\/ddr552","article-title":"Long-term memory deficits in Huntington\u2019s disease are associated with reduced CBP histone acetylase activity","volume":"21","author":"Giralt","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0512","article-title":"Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington\u2019s disease","volume":"10","author":"Blum","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejphar.2013.06.035","article-title":"Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats","volume":"714","author":"Thakur","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nbd.2010.01.013","article-title":"Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF","volume":"38","author":"Puerta","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"14220","DOI":"10.1073\/pnas.2003277117","article-title":"cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases","volume":"117","author":"VerPlank","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1113\/JP273607","article-title":"Proteasome dysfunction in cardiomyopathies","volume":"595","author":"Gilda","year":"2017","journal-title":"J. Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","article-title":"New Pharmacological Strategies to Increase cGMP","volume":"67","author":"Buglioni","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0271678X17747177","article-title":"The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review","volume":"38","author":"Pauls","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40618-018-0977-y","article-title":"The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: In vivo and in vitro evidence","volume":"42","author":"Giannattasio","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Corinaldesi, C., Ross, R.L., Abignano, G., Antinozzi, C., Marampon, F., di Luigi, L., Buch, M.H., Riccieri, V., Lenzi, A., and Crescioli, C. (2021). Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062894"},{"key":"ref_131","first-page":"1238","article-title":"Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy","volume":"39","author":"Corinaldesi","year":"2016","journal-title":"Inflammation"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"ElHady, A.K., El-Gamil, D.S., Abdel-Halim, M., and Abadi, A.H. (2023). Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091266"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10557-021-07275-y","article-title":"Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety","volume":"37","author":"Roy","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1078-0432.CCR-15-1900","article-title":"Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy","volume":"22","author":"Catalano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Catalano, S., Panza, S., Augimeri, G., Giordano, C., Malivindi, R., Gelsomino, L., Marsico, S., Giordano, F., Gy\u0151rffy, B., and Bonofiglio, D. (2019). Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. Cancers, 11.","DOI":"10.3390\/cancers11111740"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Tiwari, A.K., and Chen, Z.S. (2013). Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00082"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Paronetto, M.P., and Crescioli, C. (2024). Rethinking of phosphodiesterase 5 inhibition: The old, the new and the perspective in human health. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1461642"},{"key":"ref_138","unstructured":"(2024, August 03). Phosphodiesterase Type 5 Inhibitors for the Treatment of BPH\/LUTS Evidence Summary and Recommendations, Available online: https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/PDE5I_BPH-LUTS_CR_Mar2022.pdf."},{"key":"ref_139","first-page":"CD014089","article-title":"Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud\u2019s phenomenon","volume":"11","author":"Maltez","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_140","unstructured":"Dhaliwal, A., and Gupta, M. (2023). PDE5 Inhibitors, StatPearls Publishing."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/20\/1720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:15:29Z","timestamp":1760112929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/20\/1720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":140,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cells13201720"],"URL":"https:\/\/doi.org\/10.3390\/cells13201720","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}